Qudexy® XR (topiramate) Extended-Release Capsules are indicated for:
- Migraine: Prophylaxis of migraine headache in adults and adolescents 12 years of age and older.
- Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures: Initial monotherapy in patients 2 years and older with partial-onset or primary generalized tonic-clonic seizures and adjunctive therapy in patients 2 years and older with partial-onset or primary generalized tonic-clonic seizures.
- Lennox-Gastaut Syndrome (LGS): Adjunctive therapy in patients 2 years and older with seizures associated with Lennox-Gastaut syndrome.
PREVAIL Epilepsy Trial
Qudexy® XR is the only extended-release topiramate formulation backed by PREVAIL Phase 3 data in patients with epilepsy.